BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33602765)

  • 1. Painful, reappearing eruption in a medically complex 4-year-old.
    Sooy M; Randell RL; Tchapyjnikov D; Werner K; Nazareth-Pidgeon K
    BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33602765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infrequent SCN9A mutations in congenital insensitivity to pain and erythromelalgia.
    Klein CJ; Wu Y; Kilfoyle DH; Sandroni P; Davis MD; Gavrilova RH; Low PA; Dyck PJ
    J Neurol Neurosurg Psychiatry; 2013 Apr; 84(4):386-91. PubMed ID: 23129781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An atypical case of SCN9A mutation presenting with global motor delay and a severe pain disorder.
    Meijer IA; Vanasse M; Nizard S; Robitaille Y; Rossignol E
    Muscle Nerve; 2014 Jan; 49(1):134-8. PubMed ID: 23893323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gain-of-function mutation of a voltage-gated sodium channel Na
    Tanaka BS; Nguyen PT; Zhou EY; Yang Y; Yarov-Yarovoy V; Dib-Hajj SD; Waxman SG
    J Biol Chem; 2017 Jun; 292(22):9262-9272. PubMed ID: 28381558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A severe case of primary erythromelalgia presenting as small fiber neuropathy with a novel SCN9A mutation.
    Watabe D; Tominaga M; Toyama S; Takamori K; Nakano H; Amano H
    J Dermatol; 2023 Jul; 50(7):938-941. PubMed ID: 36815391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary erythromelalgia in a 12-year-old boy: positive response to sodium channel blockers despite negative SCN9A mutations.
    Jakob A; Creutzfeldt R; Staszewski O; Winterpacht A; Berner R; Hufnagel M
    Klin Padiatr; 2012 Sep; 224(5):309-12. PubMed ID: 22170168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation in Na
    Haehner A; Hummel T; Heinritz W; Krueger S; Meinhardt M; Whitcroft KL; Sabatowski R; Gossrau G
    Eur J Pain; 2018 Nov; 22(10):1767-1773. PubMed ID: 29934995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel SCN9A Mutation (F826Y) in Primary Erythromelalgia Alters the Excitability of Nav1.7.
    Wu B; Zhang Y; Tang H; Yang M; Long H; Shi G; Tang J; Shi X
    Curr Mol Med; 2017; 17(6):450-457. PubMed ID: 28990532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilateral congenital corneal anesthesia in a patient with SCN9A mutation, confirmed primary erythromelalgia, and paroxysmal extreme pain disorder.
    Kim DT; Rossignol E; Najem K; Ospina LH
    J AAPOS; 2015 Oct; 19(5):478-9. PubMed ID: 26486037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nav1.7-A1632G Mutation from a Family with Inherited Erythromelalgia: Enhanced Firing of Dorsal Root Ganglia Neurons Evoked by Thermal Stimuli.
    Yang Y; Huang J; Mis MA; Estacion M; Macala L; Shah P; Schulman BR; Horton DB; Dib-Hajj SD; Waxman SG
    J Neurosci; 2016 Jul; 36(28):7511-22. PubMed ID: 27413160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric Erythromelalgia and SCN9A Mutations: Systematic Review and Single-Center Case Series.
    Arthur L; Keen K; Verriotis M; Peters J; Kelly A; Howard RF; Dib-Hajj SD; Waxman SG; Walker SM
    J Pediatr; 2019 Mar; 206():217-224.e9. PubMed ID: 30416015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary erythromelalgia successfully treated with intravenous immunoglobulin.
    Moody S; Pacheco S; Butler IJ; Koenig MK
    J Child Neurol; 2012 Jul; 27(7):922-3. PubMed ID: 22156790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel.
    Natkunarajah J; Atherton D; Elmslie F; Mansour S; Mortimer P
    Clin Exp Dermatol; 2009 Dec; 34(8):e640-2. PubMed ID: 19549232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel SCN9A mutations underlying extreme pain phenotypes: unexpected electrophysiological and clinical phenotype correlations.
    Emery EC; Habib AM; Cox JJ; Nicholas AK; Gribble FM; Woods CG; Reimann F
    J Neurosci; 2015 May; 35(20):7674-81. PubMed ID: 25995458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case of Pediatric Auricular Erythromelalgia.
    Reese A; DiNardo L; Powers K; Carr MM
    Cureus; 2022 Jan; 14(1):e21088. PubMed ID: 35155035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical treatments for erythromelalgia.
    Raef HS; Williams M; Fedeles F
    Dermatol Ther; 2022 Nov; 35(11):e15860. PubMed ID: 36164837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autonomic dysfunction in SCN9A-associated primary erythromelalgia.
    Kim MK; Yuk JW; Kim HS; Park KJ; Kim DS
    Clin Auton Res; 2013 Apr; 23(2):105-7. PubMed ID: 23152140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary erythromelalgia: a review.
    Tang Z; Chen Z; Tang B; Jiang H
    Orphanet J Rare Dis; 2015 Sep; 10():127. PubMed ID: 26419464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel mutations mapping to the fourth sodium channel domain of Nav1.7 result in variable clinical manifestations of primary erythromelalgia.
    Cregg R; Laguda B; Werdehausen R; Cox JJ; Linley JE; Ramirez JD; Bodi I; Markiewicz M; Howell KJ; Chen YC; Agnew K; Houlden H; Lunn MP; Bennett DL; Wood JN; Kinali M
    Neuromolecular Med; 2013 Jun; 15(2):265-78. PubMed ID: 23292638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Life-threatening hypothermia in a child with primary erythromelalgia.
    Matarneh B; Witman P
    Pediatr Dermatol; 2022 Jan; 39(1):135-136. PubMed ID: 34888934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.